Nemifitide: Dosing Protocols
Dosing guidelines, reconstitution, and administration information
๐TL;DR
- โข2 dosing protocols documented
- โขReconstitution instructions included
- โขStorage: Store lyophilized research material at -20 degrees C. Clinical trial formulations were stored refrigerated at 2-8 degrees C.
Protocol Quick-Reference
Major depressive disorder (investigational)
Dosing
Amount
0.2 mg/kg
Frequency
Daily
Duration
5-10 days
Administration
Route
SCSchedule
Once daily
Timing
Daily subcutaneous injection for 5 consecutive days; extended protocols use 10 consecutive days
Cycle
Duration
5-10 days
Repeatable
Yes
โ๏ธ Suggested Bloodwork (3 tests)
CBC with differential
When: Baseline
Why: Baseline blood cell counts
CMP (Comprehensive Metabolic Panel)
When: Baseline
Why: Liver and kidney function baseline
CBC
When: After treatment course
Why: Monitor for any changes during treatment
๐ก Key Considerations
- โNot FDA-approved: reached Phase 3 but has not been approved for marketing in any country
- โInactive orally; must be administered by subcutaneous injection
- โResponse correlates with plasma concentration; variable bioavailability may affect efficacy
Unlock dosing protocols
Free access to research-backed dosing information for all peptides.
150+ peptide profiles ยท 30+ comparisons ยท 18 research tools
| Purpose | Dose | Frequency | Duration | Notes |
|---|---|---|---|---|
| Phase 2 Depression Trial (Feighner et al., 2000) | 0.2 mg/kg subcutaneous | Daily | 5 consecutive days | Significant antidepressant effects in patients achieving adequate plasma concentrations. Rapid onset within 5-7 days. |
| Extended Phase 2 Protocol | 0.2 mg/kg subcutaneous | Daily | 10 consecutive days | Extended treatment course evaluated in some trials. Maintained safety profile with continued efficacy. |
Unlock full dosage protocols
Free access to complete dosing tables and protocol details.
150+ peptide profiles ยท 30+ comparisons ยท 18 research tools
๐Reconstitution Instructions
Nemifitide was supplied as a ready-to-inject solution for subcutaneous administration in clinical trials. Research-grade material (diTFA salt) requires reconstitution in sterile water or saline.
Recommended Injection Sites
- โSubcutaneous (abdomen, thigh, or upper arm)
๐งStorage Requirements
Store lyophilized research material at -20 degrees C. Clinical trial formulations were stored refrigerated at 2-8 degrees C.
Community Dosing Protocols
Compare these clinical doses with what 5+ community members report using.
Based on 5+ community reports
View community protocolsResearch Tools
Before You Begin
Review safety warnings and contraindications before starting any protocol.
Important Disclaimer#
Nemifitide is not approved for human use in any country. All dosing information is derived from clinical trials and is provided for research reference only.
Clinical Trial Dosing#
Phase 2 Depression Trials#
The primary clinical dosing regimen employed 0.2 mg/kg subcutaneously daily for 5 consecutive days. In the Feighner et al. (2000) pivotal study, 52 patients with major depression were randomized to nemifitide or placebo. Patients achieving adequate plasma concentrations showed statistically significant improvement on depression rating scales.
Extended Protocols#
Some trials evaluated 10-day treatment courses at the same 0.2 mg/kg dose, demonstrating sustained efficacy and safety. The re-treatment study showed maintained effectiveness when patients received a second course of treatment.
Pharmacokinetic Considerations#
Despite a short plasma half-life (15-30 minutes), nemifitide's antidepressant effects develop over 5-7 days and persist beyond the treatment period. This pharmacodynamic/pharmacokinetic dissociation suggests that the therapeutic effect depends on receptor-level adaptations rather than sustained plasma drug levels.
Route of Administration#
Nemifitide is inactive when taken orally and must be administered by subcutaneous injection. Clinical trials used daily SC injections for 5-10 day courses.
Reconstitution Instructions#
Research-grade nemifitide (diTFA salt) should be reconstituted in sterile water or normal saline. Clinical trial formulations were provided as ready-to-inject solutions.
Storage Guidelines#
Store lyophilized peptide at -20 degrees C. Reconstituted solutions should be refrigerated at 2-8 degrees C and used promptly.
Dosing Context#
Nemifitide belongs to the Neuropeptide category of research peptides. Dosing protocols for Nemifitide are derived from available clinical trial data. These protocols are provided for research reference only and do not constitute medical advice. Actual dosing decisions should be made by qualified healthcare providers based on individual patient factors.
Research Protocols#
The following dosing protocols have been documented in clinical research for Nemifitide:
Phase 2 Depression Trial (Feighner et al., 2000)#
Dose: 0.2 mg/kg subcutaneous
Frequency: Daily
Duration: 5 consecutive days
Significant antidepressant effects in patients achieving adequate plasma concentrations. Rapid onset within 5-7 days.
Extended Phase 2 Protocol#
Dose: 0.2 mg/kg subcutaneous
Frequency: Daily
Duration: 10 consecutive days
Extended treatment course evaluated in some trials. Maintained safety profile with continued efficacy.
Reconstitution and Preparation#
Nemifitide was supplied as a ready-to-inject solution for subcutaneous administration in clinical trials. Research-grade material (diTFA salt) requires reconstitution in sterile water or saline.
Injection Sites#
Recommended injection sites for Nemifitide include:
- Subcutaneous (abdomen, thigh, or upper arm)
Site rotation is recommended to minimize local tissue reactions and ensure consistent absorption.
Storage Requirements#
Store lyophilized research material at -20 degrees C. Clinical trial formulations were stored refrigerated at 2-8 degrees C.
Related Reading#
Subscribe to see vendor options
Free access to verified vendor scores, pricing, and suppliers.
150+ peptide profiles ยท 30+ comparisons ยท 18 research tools
Protocol updates
Get notified when we update dosing protocols or publish related comparisons.
Frequently Asked Questions About Nemifitide
Explore Further
Medical Disclaimer
This website is for educational and informational purposes only. The information provided is not intended to diagnose, treat, cure, or prevent any disease. Always consult with a qualified healthcare professional before using any peptide or supplement.